Abstract
There is wide interpatient variability in drug response and toxicity to standard doses of most anticancer medications. Genetic polymorphisms in genes encoding metabolic enzymes, receptors and drug transporters targeted by anticancer medications are often found, in part, to be responsible for the observed variability. Approximately 80% of all sequence variations residing in genes is in the form of single nucleotide polymorphisms or SNPs. The location of SNPs can be in the protein coding sequence, regulatory regions or at exon-intron boundaries of genes. Adverse drug reactions resulting from these sequence variations are due to changes in the activity of the encoded protein (in many instances the protein is non-functional) or perturbations in the level of gene expression. The goal of pharmacogenetic testing is to identify genetic polymorphisms that predispose patients to an adverse drug reaction, thereby allowing the health care provider to make informed decisions pertaining to the type of drug, dosage and dosage scheduling to be administered.
Keywords: Pharmacogenetics, single nucleotide polymorphisms, genetic variation, thiopurine S-methyltransferase, thymidylate synthase, dihydropyrimidine dehydrogenase, ATP-binding cassette transporters, multidrug resistance-associated protein, cancer health disparities.
Anti-Cancer Agents in Medicinal Chemistry
Title: Pharmacogenetics of Drug Metabolizing Enzymes and Transporters: Effects on Pharmacokinetics and Pharmacodynamics of Anticancer Agents
Volume: 10 Issue: 8
Author(s): Norman H. Lee
Affiliation:
Keywords: Pharmacogenetics, single nucleotide polymorphisms, genetic variation, thiopurine S-methyltransferase, thymidylate synthase, dihydropyrimidine dehydrogenase, ATP-binding cassette transporters, multidrug resistance-associated protein, cancer health disparities.
Abstract: There is wide interpatient variability in drug response and toxicity to standard doses of most anticancer medications. Genetic polymorphisms in genes encoding metabolic enzymes, receptors and drug transporters targeted by anticancer medications are often found, in part, to be responsible for the observed variability. Approximately 80% of all sequence variations residing in genes is in the form of single nucleotide polymorphisms or SNPs. The location of SNPs can be in the protein coding sequence, regulatory regions or at exon-intron boundaries of genes. Adverse drug reactions resulting from these sequence variations are due to changes in the activity of the encoded protein (in many instances the protein is non-functional) or perturbations in the level of gene expression. The goal of pharmacogenetic testing is to identify genetic polymorphisms that predispose patients to an adverse drug reaction, thereby allowing the health care provider to make informed decisions pertaining to the type of drug, dosage and dosage scheduling to be administered.
Export Options
About this article
Cite this article as:
H. Lee Norman, Pharmacogenetics of Drug Metabolizing Enzymes and Transporters: Effects on Pharmacokinetics and Pharmacodynamics of Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/187152010794474019
DOI https://dx.doi.org/10.2174/187152010794474019 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Studies Most Employed in the Discovery of New Antimicrobial Agents
Current Medicinal Chemistry MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion
Current Medicinal Chemistry Flavonoids: Recent Advances as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Meet Our Editorial Board Member
Current Cancer Drug Targets RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses
Current Drug Targets Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Synthesis of Nitroaromatic Compounds as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
Current Pharmaceutical Design Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Cardiovascular & Hematological Disorders-Drug Targets The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Fecal DNA Genotyping: A Non-invasive Approach to Characterize Mouse Models for Nutrigenomics Cancer Chemoprevention Studies
Current Pharmacogenomics and Personalized Medicine Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry MicroRNA-34a: Role in Cancer and Cardiovascular Disease
Current Drug Targets Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Interplay Between ACE2 and Angiotensin-(1-7) in the Regulation of Blood Pressure
Current Hypertension Reviews